Mutational and immune gene expression profiling at relapse in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (pbo) in the COMBI-AD trial.
Reinhard Dummer(University Hospital of Zurich), Georgina V. Long(The University of Sydney), Mario Mandalà(University of Perugia), James E. Garrett, Jan C. Brase(Novartis (Switzerland)), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Marta Nyakas(Oslo University Hospital), Dirk Schadendorf(National Center for Tumor Diseases), Axel Hauschild(University Hospital Schleswig-Holstein), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Richard Kefford(Broad Institute), James Larkin(Trinity College Dublin), Victoria Atkinson(The University of Queensland), Bijoyesh Mookerjee(Novartis (United States)), Catarina D. Campbell(Broad Institute), Mario Santinami(Fondazione IRCCS Istituto Nazionale dei Tumori), Andrew Haydon(The Alfred Hospital), John M. Kirkwood(UPMC Hillman Cancer Center), Caroline Robert(Institut Gustave Roussy), Paola Aimone(Novartis (Switzerland))
Cited by 1
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k